The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 27 rounds in the feed, most often in Biotech.
Venture capitalsofinnovapartners.comRounds from 2017-10-30 to 2026-11-05
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
T-Therapeutics A biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases | Series B Verified against 1 of 60 sources | $133M | 2026-11-05 | [ PART ] |
Alethio Therapeutics A biopharmaceutical company developing therapies for myeloproliferative neoplasms (MPNs) | Series A |
| $90M |
| 2026-11-05 |
| [ LEAD ] |
DMC Biotechnologies A U.S.-based health ingredient company developing high-purity, science-backed bioactives through precision fermentation | Series B Verified against 4 of 7 sources | $18M | 2026-10-26 | [ LEAD ] |
STAR Therapeutics They develop and provide antibody therapies for patients with serious diseases. | Funding round Verified against 1 of 9 sources | $200M | 2026-10-22 | [ PART ] |
IMIO IMIO develops dependable biologicals for crop performance, nutrient efficiency, and soil function. | Seed Verified against 4 of 49 sources | $12M | ~ 2026-10-19 | [ LEAD ] |
HighLife HighLife develops a transcatheter system for replacing the mitral valve in patients with heart valve disease. | Funding round Verified against 4 of 9 sources | $90M | 2026-09-22 | [ LEAD ] |
Bionyra Pharma Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immune-mediated inflammatory diseases. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2026-06-22 | [ LEAD ] |
Ingenix An AI biology company | Seed ext. Verified against 2 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $14.8M | 2026-06-03 | [ LEAD ] |
CellCentric A drug-discovery platform | Series D Verified against 4 of 7 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $220M | 2026-05-06 | [ PART ] |
Coultreon Biopharma Develop autoimmune disease treatments | Series A Verified against 1 of 5 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $125M | 2026-04-28 | [ LEAD ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-11-17 | [ PART ] |
AAVantgarde AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet need | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $141M | 2025-11-03 | [ PART ] |
Hemab Therapeutics Hemab develops targeted therapies for bleeding disorders, focusing on conditions like Glanzmann Thrombasthenia and Von Willebrand Disease. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $157M | 2025-10-27 | [ LEAD ] |
Expedition Therapeutics Expedition Therapeutics develops novel treatments for inflammatory and respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD). | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2025-10-09 | [ LEAD ] |
STAR Therapeutics They develop and provide antibody therapies for patients with serious diseases. | Series D Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2025-09-30 | [ PART ] |
Galvanize Therapeutics Galvanize Therapeutics designs pulsed electric field energy devices for surgical ablation of soft tissue, targeting healthcare providers and hospitals. | Series C Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-09-03 | [ LEAD ] |
ArtBio ARTBIO develops alpha radioligand therapies focused on cancer treatment aimed at healthcare providers and patients. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $132M | 2025-07-29 | [ LEAD ] |
GlycoEra Biologics aimed at precision immunology, targeting and degrading specific proteins associated with autoimmune diseases for improved patient outcomes. | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2025-05-27 | [ PART ] |
Atsena Therapeutics Atsena Therapeutics develops gene therapies for inherited retinal diseases, targeting conditions like X-linked retinoschisis and Leber congenital amaurosis. | Series C Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2025-04-02 | [ PART ] |
T-Therapeutics A biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $59.8M | 2023-11-15 | [ LEAD ] |
STAR Therapeutics They develop and provide antibody therapies for patients with serious diseases. | Series C Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $90M | 2023-09-05 | [ LEAD ] |
Enginzyme Enginzyme sells enzyme-based biomanufacturing solutions for cleaner and more efficient manufacturing processes, targeting the biotech sector. | Series B Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $22.3M | 2022-12-22 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $153M | 2021-07-27 | [ PART ] |
Atsena Therapeutics Atsena Therapeutics develops gene therapies for inherited retinal diseases, targeting conditions like X-linked retinoschisis and Leber congenital amaurosis. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $55M | 2020-12-16 | [ LEAD ] |
DMC Biotechnologies A U.S.-based health ingredient company developing high-purity, science-backed bioactives through precision fermentation | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $10.3M | 2019-06-09 | [ LEAD ] |
HighLife HighLife develops a transcatheter system for replacing the mitral valve in patients with heart valve disease. | Series B Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $36.5M | 2019-01-17 | [ PART ] |
HighLife HighLife develops a transcatheter system for replacing the mitral valve in patients with heart valve disease. | Funding round Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $14.3M | 2017-10-30 | [ LEAD ] |